In this direction, Han et al. investigated the anti-cancer activity of A549 and H441 lung cancer cells using two novel cyclic amide-bearing hydroxamic acid-based HDAC inhibitors SL142 and SL325. This evidence concerns the gene HDAC9 and lung carcinoma.